Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer - a multicentre evaluation.

James Cairns^1,2, Salman Arain^3,4, Amarnath Challapalli⁵, Amalia Stavropoulos⁵, Tamir Ali⁶, Daniel Ward⁶, John Sage⁷, Georgia Ionescu⁷, Julien M Y Willaime⁷, Russell Frood^3,4, Amit Bahl⁵, George Petrides⁶, Andrew Scarsbrook^3,4

¹Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. james.cairns2@nhs.net.

²Faculty of Medicine and Health, University of Leeds, Leeds, UK. james.cairns2@nhs.net.

³Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

⁴Faculty of Medicine and Health, University of Leeds, Leeds, UK.

⁵University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

⁶Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

⁷Mirada Medical Ltd, Oxford, UK.

PubMed DOI

Abstract

PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT is widely used in prostate cancer management, but unspecific bone uptake (UBU) remains a diagnostic challenge particularly with [18F]PSMA-1007. Bone uptake metastatic probability (BUMP) score - a composite imaging-clinical model, was compared with PSMA Reporting and Data System (PSMA-RADS, Version 2) for predicting skeletal metastases in UB…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.